As a key strategy in enhancing patient results, incorporation of adjunctive osimertinib after chemoradiotherapy for lung tumor has emerged.Aiming to bolster the effectiveness of initial therapy through targeting remaining disease and avoiding recurrence, this original approach.This article explores the reasoning behind employing adjunctive osimertinib post-chemoradiotherapy, discussing the related advantages, challenges, and possible future developments.To improve cancer-free survival is one of the main goals of adjunctive osimertinib post chemoradiation.this part discusses how, by effectively targeting distinct genetic alterations, like EGFR and ALK pathways, that are frequently associated with lung tumor, the…
